Presentation TCT 2017

FDA Perspectives on TAVR Label Expansion Using Real-World Evidence, Valve Degeneration, and Embolic Protection Devices

Presenter: John C Laschinger

October 31, 2017

REGISTER for free or LOG IN to view this content

FDA Perspectives on TAVR Label Expansion Using Real-World Evidence, Valve Degeneration, and Embolic Protection Devices

Structural Heart

Presentation

TCT 2017

Aortic Valve

Up Next

Presentation TCT 2017

LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates

Presenter: Michael J. Reardon

October 31, 2017

More slides +

Presentation TCT 2017

Master Perspectives: Compared to Medical Therapy, Does CTO PCI Improve Prognosis, or Are the Main Benefits Symptomatic Improvement?

Presenter: Barry D. Rutherford

October 31, 2017

Presentation TCT 2017

Transpericardial Access for LAA Closure

Presenter: Krzysztof Bartus

October 31, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.